weight loss

Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide (Wegovy), lost about 33 pounds.

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling to lessen the budgetary squeeze from fast-rising costs.

Experts tend to focus on the kinds of foods you can eat to improve your health. But the speed at which you devour your dinner matters just as much.

Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big employers are adding coverage, but their commitment isn’t guaranteed.

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar GLP-1 drugs if they are struggling with weight. That support doesn't go for teens.

Will you still carry this added weight on New Year's Day 2026? For a quarter of us, that is probably going to prove true, according to a survey.

A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans. But it’s unclear if it will will have support of the Trump administration.

Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the medications.

After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.